TMIC-42. LOCAL TISSUE METABOLOMICS BASED BIOMARKERS OF RESPONSE TO THERAPY FOR GLIOBLASTOMA

Glioblastoma (GBM) is a common deadly malignant brain cancer of the central nervous system (CNS), with a median survival of 12–15 months. Scientific advancements are lacking in developing effective therapies for both primary GBM, as well as secondary GBMs, that typically originate as malignant trans...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Rajani, Karishma, Carlstrom, Lucas, Jacobs, Joshua, Schroeder, Mark, Olson, Ian, Wang, Xuewei, Sarkaria, Jann, Burns, Terry
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Tumor Microenvironment
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846014/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.1076
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars